Site Editor

Thomas Flaig, MD

Advertisement
Advertisement

Long-Term Safety Analyses of Maintenance Avelumab From JAVELIN Bladder 100

By: Kayci Reyer
Posted: Monday, July 10, 2023

According to post hoc safety analyses from the phase III JAVELIN Bladder 100 trial after a minimum follow-up of 2 years, presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 4516), first-line avelumab, an immune checkpoint inhibitor, may be a safe option for maintenance therapy in patients with advanced urothelial carcinoma. “These results further support the use of avelumab [first-line] maintenance until [disease] progression as standard of care for [patients with advanced urothelial carcinoma] without [disease] progression after [first-line] platinum-based chemotherapy,” concluded Joaquim Bellmunt, MD, PhD, of Dana-Farber Cancer Institute, Boston, and colleagues.

The study included patients with unresectable locally advanced or metastatic urothelial cancer who had not experienced disease progression after first-line platinum-based chemotherapy. The ad hoc analyses evaluated safety outcomes among patients who received at least one dose of maintenance avelumab. Median follow-up was 38 months, median duration of treatment was 5.8 months, and median number of infusions was 11.5.

Overall, 269 patients (78.2%) experienced treatment-related adverse events, and 67 patients (19.5%) experienced treatment-related adverse events of grade 3 or higher, the most common of which were increases in lipase (3.5%) and amylase (2.3%). For 40 patients (11.6%), a treatment-related adverse event resulted in treatment discontinuation.

A total of 111 patients (32.3%) reported immune-related adverse events, which occurred at grade 3 or higher for 26 patients (7.6%) and were considered serious for 18 patients (5.2%). For 21 patients (6.1%), an immune-related adverse event resulted in treatment discontinuation. Immune-related adverse events occurred after 12 months of treatment in 27 of the 118 patients who underwent avelumab treatment for at least 1 year.

Disclosures: For full disclosures of the study authors, visit coi.asco.org.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.